Picture [LSA] – The Business Web Portal 650x89px
Organisation › Details

IFM Therapeutics (US, acquired 8/17 by BMS)

IFM Therapeutics is a privately held biopharmaceutical company based in Boston, Massachusetts and Bonn, Germany. Seeded by Atlas Venture, the company was founded in 2015 by an international group of preeminent scientists and physicians to discover and develop small molecules that modulate novel targets in the innate immune system as next generation therapies for cancer, autoimmunity, and inflammatory disorders. In June 2016, IFM closed a $27 million Series A financing led by Atlas Venture and Abingworth, with participation from Novartis. Drugs in the IFM portfolio are expected to significantly improve upon standard of care agents in terms of efficacy and safety. *


Period Start 2015-01-01 established
  Group Bristol-Myers Squibb (BMS) (Group)
  Today Bristol-Myers Squibb Co. (BMS) (NYSE: BMY)
  Successor Bristol-Myers Squibb Co. (BMS) (NYSE: BMY)
Products Industry small-molecule drug
  Industry 2 immuno modulatory compound (IMO)
Person Person Glick, Gary D. (IFM Therapeutics 201610 CEO)
Region Region Boston, MA
  Country United States (USA)
  Street 855 Boylston Street
11th Floor
  City 02116 Boston, MA
    Address record changed: 2016-10-26
Basic data Employees n. a.
    * Document for �About Section�: IFM Therapeutics. (10/26/16). "Press Release: IFM Therapeutics Establishes German Subsidiary and Research Site". Boston, MA & Bonn.
Record changed: 2019-07-13


Picture [LSA] – The Business Web Portal 650x89px

More documents for Bristol-Myers Squibb (BMS) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px

» top